Gene silencing by synthetic U1 Adaptors

Nature Biotechnology

Volumn 27, Issue 3, 2009, Pages 257-263

  Goraczniak, Rafal ^a   Behlke, Mark A ^b   Gunderson, Samuel I ^a  

^a RUTGERS UNIVERSITY   (United States)

^b INTEGRATED DNA TECHNOLOGIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE EFFECTS; ANTISENSE; BIFUNCTIONAL; GENE-SILENCING; MECHANISM OF ACTIONS; MICROARRAY ANALYSIS; NUCLEAR RIBONUCLEOPROTEIN; NUCLEAR RNAS; PRE-MRNA; REPORTER GENES; RNA INTERFERENCES; SEQUENCE-SPECIFIC MANNERS; SMALL INTERFERING RNAS (SIRNA); SPLICING FACTORS; TARGET DOMAINS; TARGET GENES;

BIOCHEMISTRY; GENETIC ENGINEERING; NUCLEIC ACIDS; OLIGONUCLEOTIDES; TARGETS;

RNA;

OLIGONUCLEOTIDE; RAF PROTEIN; SMALL INTERFERING RNA; SMALL NUCLEAR RIBONUCLEOPROTEIN; SMALL NUCLEAR RNA; U1 ADAPTOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; EXON; GENE CONTROL; GENE EXPRESSION REGULATION; GENE SEQUENCE; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; REPORTER GENE; RNA BINDING; RNA SPLICING;

ANIMALS; BASE SEQUENCE; CELL LINE; GENE EXPRESSION REGULATION; GENE SILENCING; GENES, REPORTER; HELA CELLS; HUMANS; LUCIFERASES; MOLECULAR SEQUENCE DATA; PROTO-ONCOGENE PROTEINS C-RAF; RIBONUCLEOPROTEIN, U1 SMALL NUCLEAR; RNA, SMALL INTERFERING; RNA, SMALL NUCLEAR; SEQUENCE ANALYSIS, DNA; TRANSFECTION;

EID: 62149127652     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.1525     Document Type: Article

References (37)

1. Hannon, G.J. & Rossi, J.J. Unlocking the potential of the human genome with RNA interference. Nature 431, 371-378 (2004).
2. Kim, D.H. & Rossi, J.J. Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 8, 173-184 (2007).
3. Elbashir, S.M. et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498 (2001).
4. Beckley, S.A. et al. Reduction of target gene expression by a modified U1 snRNA. Mol. Cell. Biol. 21, 2815-2825 (2001).
5. Fortes, P. et al. Inhibiting expression of specific genes in mammalian cells using modified U1 snRNPs targeted to terminal exons of pre-mRNA. Proc. Natl. Acad. Sci. USA 100, 8264-8269 (2003).
6. Liu, P., Kronenberg, M., Jiang, X. & Rowe, D. Modified U1 snRNA suppresses expression of a targeted endogenous RNA by inhibiting polyadenylation of the transcript. Nucleic Acids Res. 32, 1512-1517 (2004).
7. Will, C.L. & Luhrmann, R. Protein functions in pre-mRNA splicing. Curr. Opin. Cell Biol. 9, 320-328 (1997).
8. Furth, P.A., Choe, W., Rex, J.H., Byrne, J.C. & Baker, C.C. Sequences homologous to 5′ splice sites are required for the inhibitory activity of papillomavirus late 3′ untranslated regions. Mol. Cell. Biol. 14, 5278-5289 (1994).
9. Guan, F., Caratozzolo, R.M., Goraczniak, R., Ho, E.S. & Gunderson, S.I. A bipartite U1 site represses U1A expression by synergizing with PIE to inhibit nuclear polyadenylation. RNA 13, 2129-2140 (2007).
10. Gunderson, S.I., Polycarpou-Schwarz, M. & Mattaj, I.W. U1 snRNP inhibits pre-mRNA polyadenylation through a direct interaction between U170K and poly(A) polymerase. Mol. Cell 1, 255-264 (1998).
11. Abad, X. et al. Requirements for gene silencing mediated by U1 snRNA binding to a target sequence. Nucleic Acids Res. 36, 2338-2352 (2008).
12. Goraczniak, R. & Gunderson, S.I. The regulatory element in the 3′-untranslated region of human papillomavirus 16 inhibits expression by binding CUG-binding protein 1. J. Biol. Chem. 283, 2286-2296 (2008).
13. Kauppinen, S., Vester, B. & Wengel, J. Locked nucleic acid (LNA), high affinity targeting of RNA for diagnostics and therapeutics. Drug Discov. Today. Technol. 2, 287-290 (2005).
14. Kurreck, J., Wyszko, E., Gillen, C. & Erdmann, V.A. Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res. 30, 1911-1918 (2002).
15. Grünweller, A. et al. Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res. 31, 3185-3193 (2003).
16. Novina, C.D. & Sharp, P.A. The RNAi revolution. Nature 430, 161-164 (2004).
17. De Paula, D., Bentley, M.V. & Mahato, R.I. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA 13, 431-456 (2007).
18. Lennox, K.A. et al. Characterization of modified antisense oligonucleotides in Xenopus laevis embryos. Oligonucleotides 16, 26-42 (2006).
19. Giles, R.V., Ruddell, C.J., Spiller, D.G., Green, J.A. & Tidd, D.M. Single base discrimination for ribonuclease H-dependent antisense effects within intact human leukaemia cells. Nucleic Acids Res. 23, 954-961 (1995).
20. Sridhar, S.S., Hedley, D. & Siu, L.L. Raf kinase as a target for anticancer therapeutics. Mol. Cancer Ther. 4, 677-685 (2005).
21. Monia, B.P., Johnston, J.F., Geiger, T., Muller, M. & Fabbro, D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med. 2, 668-675 (1996).
22. Lau, Q.C., Brüsselbach, S. & Müller, R. Abrogation of c-Raf expression induces apoptosis in tumor cells. Oncogene 16, 1899-1902 (1998).
23. McQuisten, K.A. & Peek, A.S. Identification of sequence motifs significantly associated with antisense activity. BMC Bioinformatics 8, 184 (2007).
24. Hemmings-Mieszczak, M., Dorn, G., Natt, F.J., Hall, J. & Wishart, W.L. Independent combinatorial effect of antisense oligonucleotides and RNAi-mediated specific inhibition of the recombinant rat P2X3 receptor. Nucleic Acids Res. 31, 2117-2126 (2003).
25. Rose, S.D. et al. Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res. 33, 4140-4156 (2005).
26. Kim, D.H. et al. Synthetic dsRNA dicer substrates enhance RNAi potency and efficacy. Nat. Biotechnol. 23, 222-226 (2005).
27. Meister, G. & Tuschl, T. Mechanisms of gene silencing by double-stranded RNA. Nature 431, 343-349 (2004).
28. Judge, A.D., Bola, G., Lee, A.C. & MacLachlan, I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. 13, 494-505 (2006).
29. Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178 (2004).
30. Morrissey, D.V. et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23, 1002-1007 (2005).
31. Manoharan, M. RNA interference and chemically modified small interfering RNAs. Curr. Opin. Chem. Biol. 8, 570-579 (2004).
32. Crooke, S.T. Antisense strategies. Curr. Mol. Med. 4, 465-487 (2004).
33. Zhao, J., Hyman, L. & Moore, C. Formation of mRNA 3′ ends in eukaryotes, mechanism, regulation, and interrelationships with other steps in mRNA synthesis. Microbiol. Mol. Biol. Rev. 63, 405-445 (1999).
34. Danckwardt, S., Hentze, M.W. & Kulozik, A.E. 3′ end mRNA processing, molecular mechanisms and implications for health and disease. EMBO J. 27, 482-498 (2008).
35. Ko, B. & Gunderson, S.I. Identification of new poly(A) polymerase-inhibitory proteins capable of regulating pre-mRNA polyadenylation. J. Mol. Biol. 318, 1189-1206 (2002).
36. Pfaffl, M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45 (2001).
37. Baserga, S.J. & Steitz, J.A. The diverse world of small ribonucleoproteins. In The RNA World First Edition (eds. Gesteland, R.F. and Atkins, J.F.) 359-382 (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1993).